Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat

Human and Experimental Toxicology

Volumn 31, Issue 9, 2012, Pages 945-954

  Colak, M C ^a   Parlakpinar, H ^a   Tasdemir, S ^a   Samdanci, E ^a   Kose, E ^a   Polat, A ^a   Sarihan, E ^a   Acet, A ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Cardiotoxicity; Doxorubucin; Hemodynamic Parameters; Ivabradine

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; CASPASE 3; CORALAN; CREATINE KINASE MB; DOXO TEVA; DOXORUBICIN; IVABRADINE; LACTATE DEHYDROGENASE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE CELL; HEART RATE; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; BENZAZEPINES; BLOOD PRESSURE; CARDIOTONIC AGENTS; CATALASE; CREATINE KINASE; DOXORUBICIN; FEMALE; GLUTATHIONE PEROXIDASE; HEART; HEART DISEASES; HEART RATE; L-LACTATE DEHYDROGENASE; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

RATTUS;

EID: 84866501531     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112438288     Document Type: Article

References (43)

1. Cigremis Y, Parlakpinar H, Polat A, Colak C, Ozturk F, Sahna E, et al. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol Cell Biochem. 2006 ; 285: 149-154
2. Kitakaze M. Doxorubicin, to treat cancers or to cause cardiac injury that is the question. Cardiovasc Drugs Ther. 2001 ; 15: 199-200
3. Fadillioglu E, Erdogan H, Sogut S, Kuku I. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats. J Appl Toxicol. 2003 ; 23: 71-74
4. Li T, Danelisen I, Singal PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem. 2002 ; 232: 19-26
5. Rossi NF, Maliszewska-Scislo M, Chen H. Central endothelin: effects on vasopressin and the arterial baroreflex in doxorubicin heart failure rats. Can J Physiol Pharmacol. 2008 ; 86: 343-352
6. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008 ; 117: 2377-2387
7. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004 ; 25: 363-370
8. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001 ; 104: 1477-1482
9. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin. 2005 ; 21: 1115-1122
10. Heusch G. Pleitropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol. 2008 ; 155: 970-971
11. Sahna E, Parlakpinar H, Ozer MK, Ozturk F, Ozugurlu F, Acet A. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res. 2003 ; 35: 257-261
12. Uchiyama M, Mihara M. Determination of MDA precursor in tissue by TBA test. Anal Biochem. 1978 ; 36: 271-278
13. Sun USY, Oberley LW, Li YA. Simple method for clinical assay of superoxide dismutase. Clin Chem. 1988 ; 34: 497-500
14. Aebi H Methods of Enzymatic Analysis. Bergmeyer HU, ed. New York: Academic Press ; 1974: 673-677.
15. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967 ; 70: 158-170
16. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2002 ; 283: 254-263
17. Agapito MT, Antolin Y, del Brio MT. Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res. 2001 ; 31: 23-30
18. Xu MF, Tang PL, Qian ZM. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 2001 ; 68: 889-901
19. De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment-a review. Eur J Pharmacol. 2001 ; 415: 1-11
20. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 2000 ; 207: 77-86
21. Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J Clin Invest. 1986 ; 78: 674-679
22. Rabelo E, De Angelis K, Bock P. Baroreflex sensitivity and oxidative stress in adriamycin-induced heart failure. Hypertension. 2001 ; 38: 576-580
23. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol. 1998 ; 124: 425-427
24. Tanaka N, Nozawa T, Yasumura Y, Futaki S, Hiramori K, Suga H. Heart rate proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990 ; 40: 503-521
25. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003 ; 284: 676-682
26. Ross J. Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation. Circulation. 1991 ; 83: 1076-1083
27. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008 ; 29: 2265-2275
28. Ferrari R, Cargnoni A, Ceconi C. Anti-ischemic effect of ivabradine. Pharm Res. 2006 ; 53: 435-439
29. Sulfi S, Timmis AD. Ivabradine-the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 ; 60: 222-228
30. Sevelieva I, Camm AJ. Novel If current inhibitor ivabradine: safety considerations. Adv Cardiol. 2006 ; 43: 79-96
31. Riccioni G. Ivabradine: from molecular basis to clinical effectiveness. Adv Ther. 2010 ; 27: 160-167
32. Zhang RL, Christensen LP, Tomanek RJ. Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. Anat Rec. 2010 ; 293: 839-848
33. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008 ; 154: 749-757
34. Walcher T, Bernhardt P, Vasic D, Bach H, Durst R, Rottbauer W, et al. Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration. Mediators Inflamm. 2010 ;: 751-313
35. Baumhakel M, Custodis F, Schlimmer N, Laufs U, Böhm M. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerozis. 2010 ; 212: 55-62
36. Beytur A, Binbay M, Sarihan ME, Parlakpinar H, Polat A, Gunaydin MO, et al. Dose dependent protective effect of ivabradine against ischemia reperfusion induced renal injury in rats. Kidney Blood Press Res. 2011 ; 35 (2). 114-119
37. Sarvazyan NA, Askari A, Huang WH. Effects of doxorubicin on cardiomyocytes with level of superoxide dismutase. Life Sci. 1995 ; 57: 1003-1010
38. Chattopadhyay A, Bandyopadhyay D. Vitamin E in the prevention of ischemic heart disease. Pharmacol Rep. 2006 ; 58: 179-187
39. Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer. 1996 ; 32: 21-25
40. Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001 ; 21: 151-157
41. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep. 2008 ; 60: 382-390
42. Osman AM, Nemnem MM, Abou-Bakr AA, Nassier OA, Khayyal MT. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food Chem Toxicol. 2009 ; 47: 2425-2430
43. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res. 2001 ; 43: 211-218